Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies

NCT03900442 is registered in ClinicalTrials.gov with Prescient Therapeutics, Ltd. as lead sponsor.

NCT NCT03900442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03900442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Pharmacodynamic and Pharmacokinetic Study of the Geranylgeranyltransferase I Inhibitor PTX-100 (GGTI-2418) in Patients With Advanced Malignancies
Lead sponsor
Prescient Therapeutics, Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2019
Completion date
August 8, 2025
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, ptcl